Jones Hill Capital LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$589.2M2026 Q3
Positions33
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.68.1%
What Changed This Quarter?
Top Holdings
BMRN
Biomarin Pharmaceutical
11.9%
BCRX
Biocryst Pharmaceuticals
10.0%
TVTX
Travere Therapeutics
9.6%
INDV
Supernus
9.3%
PHVS
Pharvaris N.V.
5.3%
CELC
Celcuity
5.2%
IONS
Ionis Pharmaceuticals
4.5%
SUPN
Supernus
4.4%
New / Increased
19 new · 9 increased
BCRXNEW
Biocryst Pharmaceuticals
10.0%
TVTXNEW
Travere Therapeutics
9.6%
INDVNEW
Indivior Pharmaceuticals
9.3%
CELCNEW
Celcuity
5.2%
IONSNEW
Ionis Pharmaceuticals
4.5%
PHVS
N.V. Pharvaris
5.3%
+45.7%
RLMD
Relmada Therapeutics
3.4%
+43.3%
CAPR
Capricor Therapeutics
1.4%
+112.1%
Reduced / Exited
5 reduced · 15 sold out
BMRN
Biomarin Pharmaceutical
11.9%
-18.1%
IMCR
Immunocore
2.0%
-25.1%
OLMA
Olema Pharmaceuticals
0.3%
-64.1%
INSM
Insmed
2.1%
-12.9%
TNXP
Tonix Pharmaceuticals Hldg
0.9%
-9.9%
GILDEXIT
Gilead Sciences
9.2%
ARQTEXIT
Arcutis Biotherapeutics
6.1%
MDGLEXIT
Madrigal Pharmaceuticals
6.0%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.